| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Revenue | ||||||
- | - | 115 | 260 | 475 | 409 | 81 |
Revenue | ||||||
- | - | - | - | - | - | 81 |
Operating expenses | ||||||
Research and development | ||||||
9,824 | 8,372 | 2,881 | 5,678 | 3,992 | 5,805 | 6,469 |
Acquired in-process research and development | ||||||
- | 6,767 | - | - | - | - | - |
General and administrative | ||||||
9,265 | 2,519 | 7,590 | 8,413 | 6,710 | 6,850 | 5,996 |
Loss on sale of assets (Note 6) | ||||||
-700 | - | - | - | - | - | - |
Impairment charges | ||||||
- | - | 5,800 | 9,547 | - | - | - |
Severance expense | ||||||
- | - | - | - | - | 1,864 | - |
Total operating expenses | ||||||
19,752 | 17,658 | 16,271 | 23,638 | 10,702 | 14,519 | 12,465 |
Loss from operations | ||||||
-19,752 | -17,658 | -16,156 | -23,378 | -10,227 | -14,110 | -12,384 |
Other income (expense) | ||||||
Interest income | ||||||
96 | 245 | - | - | - | - | - |
Change in fair value of Preferred B stock derivative liability | ||||||
- | - | - | - | - | 27,764 | - |
Other expense, net | ||||||
- | - | 6 | 554 | 302 | - | - |
Amortization of note discount | ||||||
- | - | - | - | - | - | 2,636 |
Interest expense | ||||||
900 | 1,000 | - | - | - | - | 233 |
Other income (expense) | ||||||
-9 | - | - | - | - | - | - |
Change in fair value of derivative liabilities | ||||||
1,117 | 1,724 | 2,010 | 4,538 | 9,940 | 9,455 | -49,330 |
Total other income (expense), net | ||||||
273 | 956 | 2,016 | 3,984 | 9,638 | 37,219 | -52,199 |
Loss before income taxes | ||||||
-19,479 | -16,702 | -14,140 | -19,394 | -589 | 23,109 | - |
Income tax benefit | ||||||
- | - | -1,302 | -556 | -73 | - | - |
Net loss | ||||||
-19,479 | -16,702 | -12,838 | -18,838 | -516 | 23,109 | -64,583 |
Unrealized gain on investments | ||||||
- | 7 | - | - | - | - | - |
Comprehensive loss | ||||||
-19,479 | -16,695 | - | - | - | - | - |
Excess of fair value of consideration transferred on conversion of Series B redeemable convertible preferred stock | ||||||
- | - | - | -3,580 | - | - | - |
Accretion of Series B redeemable convertible preferred stock | ||||||
- | - | - | 1,858 | 10,278 | 1,285 | 618 |
Net loss attributable to common stockholders | ||||||
- | - | - | -24,276 | -10,794 | 15,757 | -65,201 |
Per share information: | ||||||
Net loss per share, basic and diluted (in dollars per share) | ||||||
- | - | - | - | -1.99 | - | -0.64 |
Weighted average shares outstanding, basic and diluted | ||||||
- | - | - | - | 5,411 | - | 101,201 |
Net loss | ||||||
-19,479 | -16,702 | -12,838 | -18,838 | - | - | - |
Net loss per share, basic | ||||||
-2.49 | -3.59 | -2.01 | -24.67 | - | 4.21 | - |
Weighted average shares outstanding, basic | ||||||
7,827 | 4,652 | 6,387 | 983 | - | 3,746 | - |
Net loss per share, diluted | ||||||
-2.55 | -3.59 | -2.18 | -24.67 | - | -2.33 | - |
Weighted average shares outstanding, diluted | ||||||
8,009 | 4,652 | 6,574 | 983 | - | 5,886 | - |